Dr. Wajiha Illyas, MD

Dr. Illyas practices at Good Samaritan University Hospital St. Charles Campus in Port Jefferson, New York, part of Diocese of Rockville Centre.

Dr. Illyas' NPI, 1730613712, was assigned on April 17, 2017. Dr. Illyas holds Michigan license 420866010628.

Dr. Illyas' primary practice is Good Samaritan University Hospital St. Charles Campus, at 200 Belle Terre Road, Port Jefferson, NY 11777 in Suffolk County. The practice phone is (631) 474-6000.

Dr. Illyas' primary practice is Good Samaritan University Hospital St. Charles Campus in Port Jefferson, New York, part of Diocese of Rockville Centre. Dr. Illyas is also affiliated with NYU Langone Hospital-Suffolk. The medical group on file is Northwell Health Physician Partners Cardiology at Great Neck. Dmand AI also links Dr. Illyas to 3 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Illyas practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Illyas' primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Illyas is licensed in Michigan.

CMS data shows 371 Medicare services from Dr. Illyas across 4 procedure codes in 2024, for 145 Medicare patients. Medicare paid $37,106 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 145 Medicare patients who saw Dr. Illyas in 2024. The largest group is 75 to 84, with 60 patients. 75% of them have diabetes, and 75% have high blood pressure. 43% are also on Medicaid. Their average risk score is 3.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Illyas' median patient age at 77, with 62% women.

In 2024, Dr. Illyas wrote 189 Medicare Part D claims for 75 patients. 88% of them were for generic drugs. CMS names the drug for 25 of them, across 2 drugs with 11 or more claims each, at $199 in total drug cost. In 2018, CMS named 40 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Illyas for performance year 2024, reported through an alternative payment model (APM). Dr. Illyas accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Illyas in 2019. Dr. Illyas' most frequent co-authors are Ankuri Desai, Kalimullah Quadri, MD and Christina Ann Rager, MD.

CMS Open Payments shows 4 general payments to Dr. Illyas from 4 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Teva Pharmaceuticals USA, Inc. paid the most, $26.